JP Morgan Maintains Overweight on Anterix, Raises Price Target to $61
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Philip Cusick maintains Anterix (NASDAQ:ATEX) with a Overweight and raises the price target from $60 to $61.
JP Morgan analyst Philip Cusick maintains Anterix (NASDAQ:ATEX) with a Overweight and raises the price target from $60 to $61.